PCM
WGS icon

Portolan Capital Management’s GeneDx Holdings WGS Stock Holding History

Portolan Capital Management’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.59M Buy
102,575
+46,799
+84% +$4.27M 0.35% 82
2025
Q4 		$7.25M Buy
55,776
+11,728
+27% +$1.61M 0.39% 84
2025
Q3 		$4.75M Sell
44,048
-118,180
-73% -$12.9M 0.26% 96
2025
Q2 		$15M Buy
+162,228
New +$12.7M 0.94% 38

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Portolan Capital Management's WGS Position: Q1 2026 in Review

Portolan Capital Management increased its GeneDx Holdings (WGS) stake by 84% in Q1 2026, buying an estimated $4.27M and bringing the position to 102,575 shares worth $6.59M. The position accounts for 0.35% of the portfolio, ranked #82.

Portolan Capital Management first reported a position in WGS in Q2 2025 and has held it in 4 quarters since. The position peaked at $15M in Q2 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Portolan Capital Management held 102,575 shares of GeneDx Holdings worth $6.59M as of Q1 2026.
  • Portolan Capital Management bought 46,799 GeneDx Holdings shares in Q1 2026, an estimated $4.27M.
  • GeneDx Holdings made up 0.35% of Portolan Capital Management's portfolio in Q1 2026, its #82 holding.
  • Portolan Capital Management first reported a position in GeneDx Holdings in Q2 2025 and has held it in 4 quarters since.
  • Portolan Capital Management's GeneDx Holdings position peaked at $15M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.